pharmaphorum November 10, 2023
Valneva has claimed the accolade of becoming the first drugmaker to win FDA approval for a vaccine for chikungunya virus, a potentially life-threatening mosquito-borne disease.
The French biotech’s VLA1553 vaccine has been cleared under the Ixchiq brand for use in people aged 18 and over who are at increased risk of exposure to chikungunya, which causes fever and debilitating joint pain, as well as muscle aches, joint swelling, headache, nausea, fatigue, and rash. In severe cases, it can cause systemic complications and death.
The FDA said chikungunya – which means “disease that bends up the joints” in the language of the Makonde tribe in Africa – is an emerging global health threat with at least five million cases reported in...
Today's Sponsors
Today's Sponsor